04.15.13
ZyCal Bioceuticals, Inc. has revealed results of the first double-blind, placebo-controlled study evaluating the benefits of Cyplexinol in alleviating symptoms of osteoarthritis. The results were published in the April/May 2013 issue of Integrative Medicine: A Clinician's Journal. According to the study, participants treated with Cyplexinol reported a significant decrease in pain and stiffness, and a significant increase in quality of life (QOL) as compared to those treated with placebo.
Cyplexinol is a naturally-derived, biologically active protein complex consisting of bone morphogenetic proteins (BMPs) which stimulate bone and cartilage growth and fight inflammation. Cyplexinol is the active ingredient in Ostinol.
“Using BMPs to rebuild cartilage and down-regulate inflammatory pathways is a new and exciting approach to managing the debilitating symptoms of osteoarthritis,” said Richard Garian, DC, CCSP, one of the study investigators who also co-authored the paper. “For the first time, using rigorous study methods, we were able to demonstrate significant and measurable improvements in pain relief, functionality and quality of life in patients treated with an oral BMP - complex, Cyplexinol in as little as one week.”
In this randomized, double-blind, placebo-controlled clinical trial, 87 participants diagnosed with moderate-to-severe osteoarthritis joint pain in a weight-bearing joint (the hip or knee) were randomized to receive a daily dose of either 150 mg of Cyplexinol or placebo for 12 weeks. Investigators measured the three primary endpoints —pain, stiffness and QOL — using the Western Ontario and McMaster University (WOMAC) Osteoarthritis Index 3.1. Change in WOMAC scores from baseline to week 1, week 6 and week 12 were calculated.
Key findings demonstrated that participants treated with Cyplexinol reported:
· Significant improvement (decrease) in pain, stiffness, and QOL was observed on the WOMAC subscales for the treatment group. The change in the group’s mean scores reached significance inas early as 1 week, with a decrease in pain of 1.57 points (95% CI, 0.74-2.39; P<.0001
· Significant improvement (decrease) in pain by 3.35 points (p<0.0001) at week 12 versus those treated with placebo who reported an increase in pain by 0.35 points (p>0.05)
· Significant improvement (decrease) in stiffness by 2.95 points (p<0.0001) at week 12 versus those treated with placebo who reported a slight decrease in stiffness by 0.18 points (p>0.05)
· Significant improvement (increase) in QOL by 3.12 points (p<0.0001) at week 12 versus those treated with placebo who reported a decrease in QOL by 0.40 points (p>0.05)
For further information: http://zycalbio.com
Cyplexinol is a naturally-derived, biologically active protein complex consisting of bone morphogenetic proteins (BMPs) which stimulate bone and cartilage growth and fight inflammation. Cyplexinol is the active ingredient in Ostinol.
“Using BMPs to rebuild cartilage and down-regulate inflammatory pathways is a new and exciting approach to managing the debilitating symptoms of osteoarthritis,” said Richard Garian, DC, CCSP, one of the study investigators who also co-authored the paper. “For the first time, using rigorous study methods, we were able to demonstrate significant and measurable improvements in pain relief, functionality and quality of life in patients treated with an oral BMP - complex, Cyplexinol in as little as one week.”
In this randomized, double-blind, placebo-controlled clinical trial, 87 participants diagnosed with moderate-to-severe osteoarthritis joint pain in a weight-bearing joint (the hip or knee) were randomized to receive a daily dose of either 150 mg of Cyplexinol or placebo for 12 weeks. Investigators measured the three primary endpoints —pain, stiffness and QOL — using the Western Ontario and McMaster University (WOMAC) Osteoarthritis Index 3.1. Change in WOMAC scores from baseline to week 1, week 6 and week 12 were calculated.
Key findings demonstrated that participants treated with Cyplexinol reported:
· Significant improvement (decrease) in pain, stiffness, and QOL was observed on the WOMAC subscales for the treatment group. The change in the group’s mean scores reached significance inas early as 1 week, with a decrease in pain of 1.57 points (95% CI, 0.74-2.39; P<.0001
· Significant improvement (decrease) in pain by 3.35 points (p<0.0001) at week 12 versus those treated with placebo who reported an increase in pain by 0.35 points (p>0.05)
· Significant improvement (decrease) in stiffness by 2.95 points (p<0.0001) at week 12 versus those treated with placebo who reported a slight decrease in stiffness by 0.18 points (p>0.05)
· Significant improvement (increase) in QOL by 3.12 points (p<0.0001) at week 12 versus those treated with placebo who reported a decrease in QOL by 0.40 points (p>0.05)
For further information: http://zycalbio.com
